- Home
- DXLG vs IFRX Comparison
DXLG vs IFRX Comparison
Compare DXLG & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | IFRX |
|---|---|---|
| Founded | 1976 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 71.1M |
| IPO Year | 1987 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DXLG | IFRX |
|---|---|---|
| Price | $0.93 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.50 | ★ $8.50 |
| AVG Volume (30 Days) | 412.1K | ★ 737.0K |
| Earning Date | 12-11-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $442,120,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.95 | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.83 | $0.71 |
| 52 Week High | $3.10 | $2.77 |
Technical Indicators
Market Signals| Indicator | DXLG | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 48.92 |
| Support Level | $0.83 | $1.07 |
| Resistance Level | $1.58 | $1.16 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 12.84 | 75.52 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.